Markets:

Overview

News

Currencies

International

Treasuries

Johnson & Johnson (NY:JNJ)

227.25 -0.04 (-0.02%)

Official Closing Price Updated: 7:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

1 Super-Safe High-Yield Dividend King Stock to Buy Even if There's a Stock Market Sell-Off in 2026 ↗

Today 13:05 EST

Near a 12-year low, Kimberly-Clark may be one of the best deep value stocks for income investors to buy in 2026.

Via The Motley Fool

This Top Dividend Stock Could Achieve a Major Milestone This Year. Is It a Buy? ↗

January 30, 2026

Johnson & Johnson is a picture of stability.

Via The Motley Fool

Topics Intellectual Property

Economic Alarm Bells: LEI Index Slips 0.3% as US Economy Navigates a Fragile 2026 Start

January 30, 2026

The Conference Board’s Leading Economic Index (LEI) recorded a 0.3% slip in its latest reading, signaling a cooling trajectory for the United States economy as it enters the new year. This downturn,...

Via MarketMinute

Topics Artificial Intelligence Economy World Trade

What Are Wall Street Analysts' Target Price for Johnson & Johnson Stock?

January 30, 2026

Although Johnson & Johnson has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Via Barchart.com

Topics ETFs World Trade

TSM or NVDA? ↗

January 29, 2026

Taiwan Semiconductor recently put up stellar fourth-quarter numbers, signaling that we've yet to reach peak AI demand. Are we in for another banner year in 2026?

Via The Motley Fool

Topics Artificial Intelligence

The Biological Singularity: How Nobel-Winning AlphaFold 3 is Rewriting the Blueprint of Life

January 28, 2026

In the annals of scientific history, few moments represent a clearer "before and after" than the arrival of AlphaFold 3. Developed by Google DeepMind and its dedicated drug-discovery arm, Isomorphic...

Via TokenRing AI

Topics Artificial Intelligence Economy

Boston Scientific to Acquire Penumbra for $14.5 Billion in Massive MedTech Consolidation

January 28, 2026

MARLBOROUGH, Mass. — In a move that has sent shockwaves through the medical technology landscape, Boston Scientific (NYSE: BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra...

Via MarketMinute

Dividend Growers: 2 Stocks That Could Be Worth $1 Trillion in 7 Years ↗

January 28, 2026

And that won't be the end of their growth stories.

Via The Motley Fool

Topics Credit Cards

3 Dividend Stocks to Hold for the Next 20 Years ↗

January 28, 2026

These aren't high-growth businesses, but they're as reliable as they come.

Via The Motley Fool

JNJ Stock Rises On Fresh FDA Approval For Multiple Myeloma Drug ↗

January 27, 2026

FDA approved Darzalex Faspro in combination with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Via Stocktwits

The $14.5 Billion Clot-Bust: Boston Scientific’s Bold Bet on Penumbra Signals a New Era of Medtech Giants

January 27, 2026

In a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (NYSE: BSX) announced on January 15, 2026, its definitive agreement to acquire Penumbra, Inc. (NYSE: PEN)...

Via MarketMinute

The $100 Billion Milestone: Johnson & Johnson Pivots from 'Steady' 2025 to Growth-Focused 2026

January 27, 2026

NEW BRUNSWICK, N.J. — Johnson & Johnson (NYSE: JNJ) has officially closed the chapter on a year many analysts described as "transitional," reporting full-year 2025 earnings that met expectations while...

Via MarketMinute

Topics Earnings Economy Government

Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile

January 27, 2026

From Johnson & Johnson

Via Business Wire

The Great Consolidation: US M&A Values Double as AI and Bio-Pharma Spark $2 Trillion Surge

January 26, 2026

As of January 26, 2026, the American corporate landscape is undergoing its most radical transformation in a generation. Following a two-year period of high-interest-rate hibernation, the United States...

Via MarketMinute

Topics Artificial Intelligence Economy

Johnson & Johnson At 52‑Week High: Momentum, Fundamentals And An Earnings Window ↗

January 26, 2026

Johnson & Johnson is trading at a 52-week high due to strong momentum and positive sentiment, with upcoming earnings set to test the sustainability of its current gains.

Via Talk Markets

Beyond Biotech—3 Healthcare Stocks for Growth-Minded Investors ↗

January 25, 2026

Via MarketBeat

2 Under-the-Radar Biotech Stocks Set to Boom in 2026 ↗

January 24, 2026

Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps.

Via The Motley Fool

Topics ETFs Intellectual Property World Trade

Johnson & Johnson 2026 Outlook: Chasing the $100 Billion Milestone Amidst Legal and Patent Hurdles

January 23, 2026

Following a resilient performance throughout 2025, healthcare giant Johnson & Johnson (NYSE: JNJ) has officially set its sights on a historic milestone for 2026. In its latest earnings report released...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Economy

2 Soaring Stocks to Hold for the Next 20 Years ↗

January 23, 2026

They can power outstanding returns while providing stability to a well-diversified portfolio.

Via The Motley Fool

Topics Intellectual Property World Trade

The Software Surge: How 2024’s $25.7 Billion M&A Explosion in Diagnostics Redefined Healthcare

January 23, 2026

The healthcare landscape underwent a seismic shift in 2024, as the industry’s major players pivoted away from traditional hardware toward high-margin diagnostic platforms and artificial intelligence...

Via MarketMinute

Topics Artificial Intelligence Economy

Johnson & Johnson Quietly Triggers a Trend Following Buy Signal ↗

January 23, 2026

Via MarketBeat

Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026

January 23, 2026

As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Economy

Is This Dividend King a Screaming Buy? ↗

January 23, 2026

Maybe there won't be any screaming about this stock. But there could be some buying.

Via The Motley Fool

Topics Intellectual Property

The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market

January 22, 2026

The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year...

Via MarketMinute

Topics Artificial Intelligence ETFs Initial Public Offering

I Correctly Predicted That These 15 Dow Jones Stocks Would Boost Their Payouts in 2025. Here's Why It Can Happen Again in 2026. ↗

January 22, 2026

The Dow is chock-full of high-quality companies that pay growing dividends.

Via The Motley Fool

Topics Stocks

Resilience in the Face of the Patent Cliff: Johnson & Johnson Forecasts Landmark 2026 Growth

January 22, 2026

NEW BRUNSWICK, N.J. – Johnson & Johnson (NYSE: JNJ) has signaled a definitive turning point in its corporate evolution, issuing a robust 2026 financial outlook that defies the gravity of the...

Via MarketMinute

Topics Earnings Economy Intellectual Property

Johnson & Johnson Analyst Raises Price Target On Several Tailwinds In 2026 ↗

January 22, 2026

Johnson & Johnson stated that there are at least three tailwinds for the Innovative Medicines business through 2026.

Via Benzinga

The Davos Pivot: Trump’s Tariff U-Turn Sends Markets Into a Greenland Glow ↗

January 22, 2026

Via Chartmill

Topics Government

This 2.4%-Yielding Dividend King Remains As Healthy As Ever ↗

January 22, 2026

Johnson & Johnson had a strong year.

Via The Motley Fool

Topics Bonds

S&P 500 Jumps Over 1% As Trump Withdraws EU Tariff Threat: Investor Sentiment Improves, Fear & Greed Index Remains In 'Neutral' Zone ↗

January 22, 2026

U.S. stocks rise as Trump withdraws tariff threats, Johnson & Johnson beats earnings expectations, and all S&P sectors close positively.

Via Benzinga

Topics Government Stocks World Trade

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.